Graybill Wealth Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.16M | Buy |
14,563
+1,254
| +9% | +$681K | 2.18% | 16 |
|
|
2025
Q4 | $7.71M | Buy |
13,309
+73
| +0.6% | +$41.3K | 2.28% | 15 |
|
|
2025
Q3 | $6.42M | Sell |
13,236
-90
| -0.7% | -$41.9K | 1.97% | 22 |
|
|
2025
Q2 | $5.4M | Buy |
13,326
+344
| +3% | +$144K | 1.76% | 27 |
|
|
2025
Q1 | $6.46M | Buy |
+12,982
| New | +$7.03M | 2.22% | 17 |
|
|
2024
Q3 | $7.74M | Buy |
12,506
+223
| +2% | +$132K | 2.87% | 9 |
|
|
2024
Q2 | $6.79M | Buy |
12,283
+32
| +0.3% | +$18.3K | 2.76% | 10 |
|
|
2024
Q1 | $7.12M | Buy |
12,251
+127
| +1% | +$71.3K | 3% | 8 |
|
|
2023
Q4 | $6.44M | Sell |
12,124
-235
| -2% | -$114K | 2.85% | 9 |
|
|
2023
Q3 | $6.26M | Sell |
12,359
-45
| -0.4% | -$24K | 3.05% | 8 |
|
|
2023
Q2 | $6.47M | Buy |
12,404
+555
| +5% | +$299K | 3.07% | 8 |
|
|
2023
Q1 | $6.83M | Sell |
11,849
-108
| -0.9% | -$60.9K | 3.48% | 6 |
|
|
2022
Q4 | $6.58M | Buy |
11,957
+178
| +2% | +$94.3K | 3.57% | 5 |
|
|
2022
Q3 | $5.97M | Sell |
11,779
-202
| -2% | -$113K | 3.55% | 6 |
|
|
2022
Q2 | $6.51M | Sell |
11,981
-284
| -2% | -$156K | 3.6% | 5 |
|
|
2022
Q1 | $7.24M | Buy |
12,265
+333
| +3% | +$191K | 3.53% | 5 |
|
|
2021
Q4 | $7.96M | Sell |
11,932
-2,319
| -16% | -$1.45M | 3.61% | 4 |
|
|
2021
Q3 | $8.14M | Sell |
14,251
-304
| -2% | -$167K | 4.01% | 3 |
|
|
2021
Q2 | $7.34M | Buy |
14,555
+214
| +1% | +$101K | 3.62% | 4 |
|
|
2021
Q1 | $6.54M | Buy |
14,341
+60
| +0.4% | +$28.6K | 3.47% | 3 |
|
|
2020
Q4 | $6.65M | Sell |
14,281
-142
| -1% | -$66.6K | 3.75% | 2 |
|
|
2020
Q3 | $6.37M | Sell |
14,423
-117
| -0.8% | -$48.3K | 4.15% | 2 |
|
|
2020
Q2 | $5.27M | Sell |
14,540
-538
| -4% | -$180K | 3.88% | 2 |
|
|
2020
Q1 | $4.28M | Sell |
15,078
-297
| -2% | -$93.7K | 3.78% | 4 |
|
|
2019
Q4 | $5M | Sell |
15,375
-429
| -3% | -$130K | 3.11% | 6 |
|
|
2019
Q3 | $4.6M | Sell |
15,804
-197
| -1% | -$56.4K | 3.11% | 8 |
|
|
2019
Q2 | $4.7M | Buy |
16,001
+69
| +0.4% | +$19K | 3.22% | 6 |
|
|
2019
Q1 | $4.36M | Sell |
15,932
-406
| -2% | -$101K | 3.05% | 7 |
|
|
2018
Q4 | $3.66M | Buy |
16,338
+585
| +4% | +$137K | 3.05% | 7 |
|
|
2018
Q3 | $3.85M | Sell |
15,753
-175
| -1% | -$40.3K | 2.79% | 11 |
|
|
2018
Q2 | $3.3M | Sell |
15,928
-473
| -3% | -$100K | 2.53% | 20 |
|
|
2018
Q1 | $3.39M | Sell |
16,401
-385
| -2% | -$80.8K | 2.58% | 18 |
|
|
2017
Q4 | $3.19M | Sell |
16,786
-3,757
| -18% | -$720K | 2.3% | 22 |
|
|
2017
Q3 | $3.89M | Buy |
20,543
+248
| +1% | +$44.9K | 2.87% | 8 |
|
|
2017
Q2 | $3.54M | Buy |
20,295
+175
| +0.9% | +$29.4K | 2.8% | 11 |
|
|
2017
Q1 | $3.09M | Buy |
20,120
+295
| +1% | +$45.1K | 2.45% | 18 |
|
|
2016
Q4 | $2.8M | Buy |
19,825
+610
| +3% | +$89.9K | 2.39% | 22 |
|
|
2016
Q3 | $3.06M | Sell |
19,215
-230
| -1% | -$35.4K | 2.84% | 10 |
|
|
2016
Q2 | $2.87M | Sell |
19,445
-7,525
| -28% | -$1.11M | 2.66% | 12 |
|
|
2016
Q1 | $3.82M | Buy |
26,970
+130
| +0.5% | +$17.4K | 3.45% | 1 |
|
|
2015
Q4 | $3.81M | Sell |
26,840
-855
| -3% | -$114K | 3.29% | 1 |
|
|
2015
Q3 | $3.39M | Buy |
27,695
+320
| +1% | +$41.7K | 2.78% | 8 |
|
|
2015
Q2 | $3.55M | Sell |
27,375
-510
| -2% | -$66.5K | 2.63% | 10 |
|
|
2015
Q1 | $3.75M | Hold |
27,885
| – | – | 2.81% | 4 |
|
|
2014
Q4 | $3.49M | Sell |
27,885
-6,535
| -19% | -$795K | 2.65% | 7 |
|
|
2014
Q3 | $4.19M | Sell |
34,420
-858
| -2% | -$104K | 3.21% | 2 |
|
|
2014
Q2 | $4.16M | Buy |
35,278
+60
| +0.2% | +$7.06K | 3.22% | 3 |
|
|
2014
Q1 | $4.24M | Sell |
35,218
-520
| -1% | -$61.8K | 3.49% | 1 |
|
|
2013
Q4 | $3.98M | Buy |
35,738
+172
| +0.5% | +$17.1K | 3.48% | 2 |
|
|
2013
Q3 | $3.28M | Sell |
35,566
-1,427
| -4% | -$129K | 2.8% | 6 |
|
|
2013
Q2 | $3.13M | Buy |
+36,993
| New | +$3.08M | 2.81% | 4 |
|
Other funds holding TMO
VCM
Graybill Wealth Management's TMO Position: Q1 2026 in Review
Graybill Wealth Management increased its Thermo Fisher Scientific (TMO) stake by 9.4% in Q1 2026, buying an estimated $681K and bringing the position to 14,563 shares worth $7.16M. The position accounts for 2.18% of the portfolio, ranked #16.
Graybill Wealth Management first reported a position in TMO in Q2 2013 and has held it in 51 quarters since. The position peaked at $8.14M in Q3 2021. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Graybill Wealth Management held 14,563 shares of Thermo Fisher Scientific worth $7.16M as of Q1 2026.
- Graybill Wealth Management bought 1,254 Thermo Fisher Scientific shares in Q1 2026, an estimated $681K.
- Thermo Fisher Scientific made up 2.18% of Graybill Wealth Management's portfolio in Q1 2026, its #16 holding.
- Graybill Wealth Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 51 quarters since.
- Graybill Wealth Management's Thermo Fisher Scientific position peaked at $8.14M in Q3 2021.
- 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Graybill Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.